hVIVO (LON:HVO) Shares Cross Above 50-Day Moving Average – Time to Sell?

hVIVO plc (LON:HVO) shares crossed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of GBX 6.41 and traded as high as GBX 9.50. hVIVO shares last traded at GBX 9.20, with a volume of 3,473,519 shares.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Shore Capital Group reaffirmed a “buy” rating and set a GBX 25 price target on shares of hVIVO in a research report on Thursday, January 29th. Peel Hunt restated an “add” rating and set a GBX 10 target price on shares of hVIVO in a research report on Thursday, November 20th. Two equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of GBX 17.50.

hVIVO Price Performance

The business has a 50-day moving average of GBX 6.41 and a 200 day moving average of GBX 7.39. The company has a current ratio of 1.61, a quick ratio of 1.16 and a debt-to-equity ratio of 33.86. The firm has a market capitalization of £65.06 million, a P/E ratio of 12.29 and a beta of 0.97.

Insider Buying and Selling

In other hVIVO news, insider Stephen Pinkerton purchased 520,000 shares of hVIVO stock in a transaction that occurred on Monday, December 15th. The stock was acquired at an average price of GBX 6 per share, with a total value of £31,200. Also, insider Yamin Mo’ Khan purchased 3,310,405 shares of the firm’s stock in a transaction on Monday, December 15th. The shares were acquired at an average price of GBX 6 per share, with a total value of £198,624.30. 5.25% of the stock is owned by corporate insiders.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.